Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain
- Citation:
- Cancer Res vol 76 (13) 3702-3710
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- 951 is parent abstract. This work was supported, in part, by the Dana Foundation; Susan G. Komen for the Cure Foundation Grant KG101016; The 26.2 with Donna Foundation (EAP); and The National Institutes of Health, National Cancer Institute Grants R01-CA152045.
- Pharmas:
- Grants:
- UG1CA189823, U10CA180821 , R01 CA152045, U10 CA025224, U10 CA180821
- Corr. Author:
- Authors:
- Keith L. Knutson Raphael Clynes Barath Shreeder Patrick Yeramian Kathleen P. Kemp Karla Ballman Kathleen S. Tenner Courtney L. Erskine Nadine Norton Donald Northfelt Winston Tan Carmen Calfa Mark Pegram Elizabeth A. Mittendorf Edith A. Perez
- Networks:
- FL028, LAPS-MA036, LAPS-MN026, PR028
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N0337, NCCTG-N98-32-52, NCCTG-N0938
- Phases:
- 2, N/A
- Keywords:
- Herceptin, immune response, breast cancer, monoclonal antibodies, vaccine, biomarker, diagnostic, antibody, T cell, survival